Modulation of telomere protection by the PI3K/AKT pathway

被引:0
作者
Marinela Méndez-Pertuz
Paula Martínez
Carmen Blanco-Aparicio
Elena Gómez-Casero
Ana Belen García
Jorge Martínez-Torrecuadrada
Marta Palafox
Javier Cortés
Violeta Serra
Joaquin Pastor
Maria A. Blasco
机构
[1] Molecular Oncology Program,Telomeres and Telomerase Group
[2] Spanish National Cancer Centre (CNIO),Experimental Therapeutics Program
[3] Spanish National Cancer Centre (CNIO),Biotechnology Program
[4] Spanish National Cancer Centre (CNIO),Experimental Therapeutics Group
[5] Vall d´Hebron Institute of Oncology (VHIO),undefined
来源
Nature Communications | / 8卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Telomeres and the insulin/PI3K pathway are considered hallmarks of aging and cancer. Here, we describe a role for PI3K/AKT in the regulation of TRF1, an essential component of the shelterin complex. PI3K and AKT chemical inhibitors reduce TRF1 telomeric foci and lead to increased telomeric DNA damage and fragility. We identify the PI3Kα isoform as responsible for this TRF1 inhibition. TRF1 is phosphorylated at different residues by AKT and these modifications regulate TRF1 protein stability and TRF1 binding to telomeric DNA in vitro and are important for in vivo TRF1 telomere location and cell viability. Patient-derived breast cancer PDX mouse models that effectively respond to a PI3Kα specific inhibitor, BYL719, show decreased TRF1 levels and increased DNA damage. These findings functionally connect two of the major pathways for cancer and aging, telomeres and the PI3K pathway, and pinpoint PI3K and AKT as novel targets for chemical modulation of telomere protection.
引用
收藏
相关论文
共 158 条
  • [1] Blackburn EH(1991)Structure and function of telomeres Nature 350 569-573
  • [2] Greider CW(1985)Identification of a specific telomere terminal transferase activity in Tetrahymena extracts Cell 43 405-413
  • [3] Blackburn EH(2011)Hallmarks of cancer: the next generation Cell 144 646-674
  • [4] Hanahan D(2015)Telomerase inhibitor imetelstat in patients with essential thrombocythemia N. Engl. J. Med. 373 920-928
  • [5] Weinberg RA(2016)Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies Genome Med 8 908-919
  • [6] Baerlocher GM(2015)A pilot study of the telomerase inhibitor imetelstat for myelofibrosis N. Engl. J. Med. 373 800-807
  • [7] Jafri MA(2001)Restoration of telomerase activity rescues chromosomal instability and premature aging in Terc-/- mice with short telomeres EMBO Rep. 2 67-77
  • [8] Ansari SA(2001)The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability Cell 107 114-117
  • [9] Alqahtani MH(2000)Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis Nat. Genet. 26 401-413
  • [10] Shay JW(2002)Transformation of normal human cells in the absence of telomerase activation Cancer Cell. 2 640-649